$2,000.00
Published: Aug-2010
Description
GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Pipeline Assessemnt and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report identifies the key trends shaping and driving the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the market positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global type 2 diabetes sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated the type 2 diabetes market to be worth $21.9 billion in 2009. The market is forecast to reach $36.1 billion by 2017 with a Compound Annual Growth Rate (CAGR) of 6% between 2010 and 2017. The main factors driving the growth of the market are the rapid growth in prevalence rates in the UK and the US, an increase in the utilization of premium priced drugs such as glitazones, an increase in prescriptions for combination drugs and an increase in the prevalence of obesity. Studies have found that obese people are three times more likely to be diagnosed with diabetes than normal people. The type 2 diabetes market has unmet needs in terms of safety and patient compliance. These unmet needs imply that the market is moderately served by the current treatment options and that significant potential exists for new entrants targeting these unmet needs.
GlobalData’s analysis reveals that there are over 251 molecules in various stages of the pipeline. Victoza, one of the promising drugs, is awaiting the US Food and Drug Administration’s (FDA) approval. The drug was approved by the European Medicines Agency (EMEA) in 2009. The late stage pipeline includes a few first-in-class and promising drugs such as dapagliflozin and D-Tagatose. These molecules differ from others as their site of action is different from that of the already marketed products. The major new classes of drugs include SGLT-2 inhibitors, 11ß HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1ß antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.
|
$2,000.00
Published: Aug-2010
Description
GlobalData, the industry analysis specialist, has released its new report, “Autistic Disorder – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Autistic Disorder market. The report identifies the key trends shaping and driving the global Autistic Disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Autistic Disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global autistic disorder therapeutics market to be valued at $331m in 2009. It is expected to grow to $765m with a compound annual growth rate (CAGR) of 11.05% by 2017. This growth is primarily attributed to the high increase in prevalence and also the rapid increase in public awareness about the disease. The existing market is weak due to a lack of diagnostic techniques, and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. Autistic disorder therapeutics market primarily consists of two products, Risperidone and Abilify, and other therapeutic classes such as anti-depressants and anti-psychotics.
|
$1,500.00
Published: Aug-2010
Description
"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research."
|
$2,000.00
Published: Jul-2010
Description
GlobalData, the industry analysis specialist, has released a new report, “Allergic Rhinitis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global allergic rhinitis market. The report identifies the key trends shaping and driving the global allergic rhinitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic rhinitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Jul-2010
Description
GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Jul-2010
Description
GlobalData, the industry analysis specialist’s new report, “Migraine - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global migraine market. The report identifies the key trends shaping and driving the global migraine market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global migraine sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Jul-2010
Description
GlobalData, the industry analysis specialist, has released a new report, “Acne - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global acne therapeutics market. The report identifies the key trends shaping and driving the global acne therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acne therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s research suggests that the global acne therapeutics market was worth $2.9 billion in 2009. It is estimated to reach revenues of $3.1 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 0.7%. The moderate increase in revenues is attributed to the overcrowding of the market with generics and the increased acceptance of alternative therapies such as photodynamic therapy and Ultraviolet (UV)/blue light therapy. The current market has several products which treat acne by targeting different etiologic factors involved in the development of acne. Solodyn (minocycline hydrochloride) currently dominates the acne therapeutics market, followed by Doryx (doxycycline). The acne therapeutics market is witnessing a shift towards combination products, using two or more effective acne treatments. The currently marketed combination products such as Duac and Ziana are projected to steadily increase their revenues.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector. GlobalData estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.
GlobalData analyzed that there are over 139 molecules in various stages of the pipeline. Vimpat, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.
|
$2,000.00
Published: Jun-2010
Description
GlobalData’s report, “HIV/AIDS – Pipeline Assessment and Market Forecasts to 2016” provides an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% for the next seven years to reach $13.7 billion by 2016. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has however succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 261 molecules currently in development for various disease segments.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist’s new report, “Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global herpes simplex sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist’s new report, “Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at $88m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 23% from $88m in 2009 to $462m by 2017. Earlier, the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead’s Letiaris and Actelion’s Tracleer are the most anticipated molecules in the IPF market.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist, has released a new report, “Hepatitis C (HCV) - Pipeline Assessment and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector. GlobalData’s analysis suggests that the global HCV market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market.
GlobalData found that the global HCV market is becoming more competitive. When seen alongside the currently marketed products and the expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in the HCV is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist’s new report, “Parkinson’s Disease – Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global Parkinson’s disease market. The report identifies the key trends shaping and driving the global Parkinson’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinson’s disease sector. GlobalData estimated the global Parkinson’s disease market to be valued at $3,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach $3,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics, weak developmental pipeline and the unknown cause of the disease continues to pose significant challenges for prospective market entrants, is expected to keep the market static. Ageing population would be a key driver of this market. The global Parkinson’s disease market is not well served with current product options and boundless scope is available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide significant market for any company.
GlobalData finds that the global Parkinson’s disease market is increasingly hampered by lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. There are 181 products in different developmental stages in 2010. Majorly, pipeline presents drugs that are aimed at symptomatic treatment of the disease. Balancing the pipeline with the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. If a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects such as dyskinesis, psychiatric side effects and obsessive compulsive behaviors. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist, has released a new report, “Dyslipidemia – Pipeline Assessment and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyslipidemia sector. GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately 3.7% from $34.4 billion in 2009 to $26.3 billion by 2016. Although the cardiovascular market expanded considerably between 2004 and 2008, growth in the seven major markets is expected to slow down from 2012. The decline is sales during this period would be due to the expiry of leading brands’ patents. Pfizer’s Lipitor, which is a major blockbuster in the dyslipidemia market, is set to expire in 2011 along with Trilipix’s. Zetia, Vyotrin, Simcor, Lescol, Livalo and Lovaza are set to expire between 2012 and 2014. Growth in the market is being driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. Cetriad, belonging to AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug. GlobalData found that there are over 98 molecules in various stages of the pipeline. Cetriad, Trilipix in combination with atorvastatin, Trilipix in combination with simvastatin, RG1658, MK-0524A, Caduet, GFT-505, AEGR-733, AMR-101 and MK-859 are some of the promising molecules in late stage dyslipidemia pipeline. These molecules differ in their targets and mechanisms of action from the existing therapies. Most of these molecules are combination products of already marketed drugs. Novelty exists in terms of using two different drugs in combination in order to provide better efficacy. Some of the drugs in the late stage pipeline such as GFT 505 and MK-0524A are completely novel to the dyslipidemia market. Though the dyslipidemia pipeline is strong in terms of first-in-class and me-too products, only a small number of products are expected to enter the market before 2016. Inspite of its strong pipeline, the dyslipidemia market is declining due to the expiries of the patents of its major blockbuster drugs.
GlobalData has found that the available treatment options have been moderately successful in meeting the market demand. The current therapeutics compete to provide rapid decreases in LDL-C (low density lipoprotein-cholesterol), TG (tryglycerides), TC (total cholesterol) levels and increases in HDL-C (high density lipoprotein-cholesterol) levels and improve patients’ overall quality of life. The treatments approved for the treatment of dyslipidemia also minimize the risk of cardiovascular disorders. Overall, there is strong competition among the currently marketed products for symptomatic treatment of the disease. Although the current dyslipidemia treatments are only symptomatic, they treat patients effectively. Hence the market for dyslipidemia is strong. However, safety remains a concern as antidyslipidemic drugs are associated with serious adverse effects such as myopathy or rhabdomylosis, liver disease and increased liver enzymes. There is significant potential for any new entrant that can cater to these unmet needs. A product with disease modifying mechanisms, a better safety profile and good efficacy is sure to achieve blockbuster drug status. Thus, a strong opportunity exists for any drug that offers better efficacy and safety than is provided by the current players.
|
$2,000.00
Published: Jun-2010
Description
GlobalData, the industry analysis specialist, has released a new report, “Type 1 Diabetes - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector. GlobalData estimates the global type 1 diabetes therapeutics market to have been valued at $2.7 billion in 2009. It is forecast to grow at 6.1% annually for the next seven years to reach $4.4 billion by 2017. This growth is primarily attributed to the increase in the average cost of therapy for type 1 diabetes and increases in the diseased and treatment seeking populations. The available treatment options are moderately successful in meeting the market demand leading to a moderate level of unmet need. A significant market potential exists to be exploited by any new entrant that will cater to the unmet needs for more convenient products with better efficacy and safety.
GlobalData finds that the emerging therapies in the pipeline are expected to capture a small portion of the unmet need. The pipeline for type 1 diabetes appears to be moderately strong. Despite the high proportion of first-in-class drugs in the pipeline, the pipeline is not very strong as the development stage products are not likely to cater to the needs of all type 1 diabetes patients. While the pipeline products are not strong enough to impact the current market considerably, the success of these products will drive the market in the long run.
|
$2,000.00
Published: May-2010
Description
GlobalData, the industry analysis specialist’s new report, “Breast Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global breast cancer market. The report identifies the key trends shaping and driving the global breast cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global breast cancer sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: May-2010
Description
GlobalData, the industry analysis specialist’s new report, “Renal Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global renal cancer market. The report identifies the key trends shaping and driving the global renal cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global renal cancer sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: May-2010
Description
GlobalData’s report, "Anemia – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anemia sector. GlobalData valued the anemia market in 2009 at $10.4 billion. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: May-2010
Description
GlobalData, the industry analysis specialist’s new report, “Hepatitis B – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global hepatitis B market. The report identifies the key trends shaping and driving the global hepatitis B market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hepatitis B (Hep B)sector.
GlobalData’s analysis revealed that the market grew at a Compound Annual Growth Rate (CAGR) of 5.9% since 2001 to reach $879m in 2009. Growth in the Hep B market will be driven by the increasing number of patients over the next few years. The current Hep B market is dominated by anti-viral therapies and this trend likely to continue, with no innovative molecules in the developmental pipeline. GlobalData’s analysis showed that the Hep B pipeline is weak in terms of the number of molecules. The pipeline molecules in the Hep B market primarily comprise of me-too molecules (five), and combination therapies (five), with efficacy and safety profiles similar to the present therapeutic options. The most promising molecules among them are combinations of entecavir plus adefovir and tenofovir plus emtricitabine.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: May-2010
Description
GlobalData’s report, “Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.
|
$2,000.00
Published: May-2010
Description
GlobalData, the industry analysis specialist’s new report, “Brain Hemorrhage - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global hemorrhage market. The report identifies the key trends shaping and driving the global hemorrhage market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hemorrhage sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: May-2010
Description
GlobalData’s report, “Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global dysmenorrhea market. The report identifies the key trends shaping and driving the global dysmenorrhea market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global dysmenorrhea sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts
The global dysmenorrhea therapeutics market was valued at $1.7 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% by 2016. This slow growth is primarily attributed to due to the lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. The current competitive landscape consists of only generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure.
|
$2,000.00
Published: Apr-2010
Description
GlobalData, the industry analysis specialist’s new report, “Acute Heart Failure – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acute heart failure (AHF) market. The report identifies the key trends shaping and driving the global AHF market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global AHF therapeutics sector. GlobalData’s analysis showed that the AHF pipeline is weak in terms of the number of molecules. The pipeline molecules in the AHF market primarily comprise of novel first-in-class (four), and me too molecules (seven) with significant efficacy and safety profiles over present therapeutic options. The most promising molecules among them are Tektruna/Rasilez, Lixivaptan, Relaxin and Cinaciguat. The market is forecast to grow at a CAGR of 2.1% from 2009 and reach a total value of $2.6 billion by 2016. Growth in the AHF market is driven by the increasing number of patients and the launch of new, promising drugs during the next few years.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Apr-2010
Description
GlobalData, the industry analysis specialist’s new report, “Liver Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.
GlobalData analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. However, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
|
$2,000.00
Published: Apr-2010
Description
GlobalData's report, “Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1.8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be important causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-label products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.
|